Effect [qlco]    
Oral [spco]    
Antiviral [phsu]    
treatment [ftcn]    
Long-term [tmco]    
Outcome [ftcn]    
radiofrequency ablation [topp]    
Therapies [ftcn]    
Hepatitis B Virus-Related Hepatocellular Carcinoma [neop]    
Object [inpr]    
This [euka]    
studies [mnob]    
Aim [idcn]    
To [qlco]    
investigate [ftcn]    
Effect [qlco]    
Oral [spco]    
Antiviral [phsu]    
treatment [ftcn]    
Prognosis [hlca]    
Hepatitis B Virus-Related Hepatocellular Carcinoma [neop]    
radiofrequency ablation [topp]    
Method [inpr]    
patient [podg]    
Histories [ocdi]    
Antiviral [phsu]    
treatment [ftcn]    
TREAT [topp]    
radiofrequency ablation [topp]    
Single [popg]    
Hepatitis B Virus-Related Hepatocellular Carcinoma [neop]    
Divide [ftcn]    
patient [podg]    
Two [qnco]    
Group [idcn]    
patient [podg]    
Receive [qlco]    
Not [ftcn]    
Receive [qlco]    
Antiviral [phsu]    
treatment [ftcn]    
base [ftcn]    
Oral [spco]    
Antiviral [phsu]    
treatment [ftcn]    
Administer [ftcn]    
radiofrequency ablation [topp]    
median [spco]    
Duration [tmco]    
Antiviral [phsu]    
treatment [ftcn]    
month [tmco]    
Hepatocellular carcinoma [neop]    
Recurrence [phpr]    
Overall [inpr]    
Survival [acty]    
Compare [acty]    
Two [qnco]    
Group [idcn]    
Full [qlco]    
Cohort [popg]    
Propensity Score [qnco]    
match [resa]    
Cohort [popg]    
Result [ftcn]    
match [resa]    
Cohort [popg]    
Probabilities [qnco]    
Hepatocellular carcinoma [neop]    
Recurrence [phpr]    
>5 [qnco]    
year [tmco]    
Non [ftcn]    
Antiviral [phsu]    
treatment [ftcn]    
Group [idcn]    
14 7 [qnco]    
Antiviral [phsu]    
treatment [ftcn]    
Group [idcn]    
Probabilities [qnco]    
Overall [inpr]    
Survival [acty]    
>5 [qnco]    
year [tmco]    
Non [ftcn]    
Antiviral [phsu]    
treatment [ftcn]    
Group [idcn]    
Antiviral [phsu]    
treatment [ftcn]    
Group [idcn]    
Analysis [lbpr]    
Show [inpr]    
Risk factor [qnco]    
Hepatocellular carcinoma [neop]    
Recurrence [phpr]    
include [ftcn]    
Large tumor [qlco]    
size [spco]    
Hazard Ratio [qnco]    
1+ [qnco]    
0.022" [qnco]    
Serum [bdsu]    
Level [qlco]    
Hazard Ratio [qnco]    
1+ [qnco]    
Serum [bdsu]    
Level [qlco]    
ng/mL [qnco]    
Hazard Ratio [qnco]    
1+ [qnco]    
Overall [inpr]    
Survival [acty]    
Associated [qlco]    
larger [qnco]    
size tumor [spco]    
Hazard Ratio [qnco]    
1+ [qnco]    
Child [aggp]    
Class [inpr]    
Hazard Ratio [qnco]    
+2 [qnco]    
Oral [spco]    
Antiviral [phsu]    
treatment [ftcn]    
radiofrequency ablation [topp]    
Associated [qlco]    
Low Risk [fndg]    
recurrence tumor [neop]    
Death [orgf]    
Hazard Ratio [qnco]    
Hazard Ratio [qnco]    
Conclusion [idcn]    
use [ftcn]    
Oral [spco]    
Antiviral [phsu]    
treatment [ftcn]    
Curative [cnce]    
radiofrequency ablation [topp]    
Associated [qlco]    
Favorable [qlco]    
Outcome [ftcn]    
recurrence tumor [neop]    
Overall [inpr]    
Survival [acty]    
patient [podg]    
Hepatitis B Virus-Related Hepatocellular Carcinoma [neop]    
